SHINE Teams with Investor Relations Firm LifeSci Advisors

JANESVILLE, Wis., Dec. 11, 2017 -- SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that it has joined forces with investor relations firm, LifeSci Advisors, LLC (“LifeSci”) to anchor its outreach to the broader investment community.  LifeSci is the leading international investor relations and corporate communications firm dedicated to the life sciences sector.

“We are excited to engage with SHINE to help build a comprehensive and impactful investor relations program,” said Michael Rice, Founder of LifeSci Partners. “SHINE is well positioned to become the leading producer of medical isotopes commonly used in the diagnosis and treatment of heart disease, cancer, and multiple other indications. We look forward to collaborating with the SHINE team to raise the company’s profile and attract new investors.”

“We have been greatly impressed with the robust infrastructure and extensive network that LifeSci Advisors brings to bear for its clients. LifeSci has an outstanding track record of recruiting excellent people and excels in investor relations,” said Greg Piefer, CEO of SHINE.  “We’re excited to move ahead with Mike and his team.”

About Mo-99
Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including Mo‑99. 

About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99.  In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals.  Learn more at http://shinemed.com.

About LifeSci Advisors, LLC
LifeSci Advisors (www.lifesciadvisors.com) is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. With a global focus and reach, the firm provides the highest quality service for its clients through its deep sector specialization. LifeSci’s team of MDs and PhDs enables the firm to better understand clients' R&D, regulatory and commercial strategies, and its team of financial services, investor relations and public relations specialists helps clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows LifeSci Advisors to provide an invaluable and unique service offering to clients.

Contact:       

Katrina Pitas
VP, Business Development
(608) 210-1060
[email protected]

Jeremy Feffer
Managing Director, LifeSci Advisors
(917) 749-1494
[email protected]